Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 5/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758628 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL935492 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL936147 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL26764119 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL3268168 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL24178687 | 1.00 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL29758625 | 0.98 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL21481160 | 0.98 | CA12 (0.45) | CA12CA1CA9CA2CES2 | |
| SCHEMBL23039655 | 0.98 | CA12 (0.43) | CA12CA1CA9CA2CES2 | |
| SCHEMBL24178778 | 0.96 | CA12 (0.42) | CA12CA1CA9CA2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230366059-A1 | METHOD FOR SEPARATION OF ADJACENT LANTHANIDE ELEMENTS | UT-BATTELLE, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230366059-A1 | METHOD FOR SEPARATION OF ADJACENT LANTHANIDE ELEMENTS | UT-BATTELLE, LLC | 2023-11-16 | — | — | US | disclosed |
| EP-4175941-A2 | METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES | UT-Battelle, LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022010759-A2 | METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES | UT-BATTELLE, LLC (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010758-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20220002229-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002229-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | GNE, GALE, ARGLU1 | CA12 834/4885CA1 414/4885CA9 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.